Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC
10.3971/j.issn.1000-8578.2021.21.0382
- VernacularTitle:放疗联合免疫检查点抑制剂在非小细胞肺癌中的临床研究进展
- Author:
Kuikui ZHU
1
;
Gang WU
Author Information
1. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
- Publication Type:Research Article
- Keywords:
Non-small cell lung cancer;
Radiotherapy;
Immune checkpoint inhibitors
- From:
Cancer Research on Prevention and Treatment
2021;48(10):916-921
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the leading cause of cancer-related deaths across the world, of which non-small cell lung cancer (NSCLC) accounts for 85%, and more than 50% of NSCLC patients were diagnosed with distant metastasis. The comprehensive treatment of NSCLC includes surgery, radiotherapy, chemotherapy, targeted therapy and immune checkpoint inhibitors. As one of the traditional treatment methods, radiotherapy plays an important role in the treatment of all stages of NSCLC, and its immunomodulatory effect has attracted much attention. The application of immune checkpoint inhibitors (ICIs) has significantly improved the prognosis of patients with local-advanced and advanced NSCLC, but the benefit population was limited. At present, the treatment mode of radiotherapy combined with ICIs has become the focus of research. This paper reviews the research progress of radiotherapy combined with ICIs in the treatment of NSCLC.
